SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 8, 2004
------------
SANGUI BIOTECH INTERNATIONAL, INC.
---------------------------------
(Exact name of Registrant as specified in its charter)
Colorado
--------
(State or other jurisdiction of Incorporation or organization
000-21271 84-1330732
--------- ----------
(Commission File Number) (I.R.S. Employer Identification No.)
Alfred-Herrhausen-Str. 44, 58455 Witten, Germany
------------------------------------------------
(Address of principal executive offices)(Zip Code)
011-49-2302-915-204
-------------------
(Registrant's telephone number, including area code)
N/A
---
(Former name or former address, if changed since last report)
Item 5. Other Events.
SanguiBioTech Gmbh enter into contract with Mercatura Cosmetics BioTech AG
--------------------------------------------------------------------------
On July 8, 2004, SanguiBioTech GmbH of Witten, Germany ("Sangui"), a wholly
owned subsidiary of Sangui BioTech International, Inc. (NASD OTCBB: SGBI) and
Mercatura Cosmetics BioTech AG of Achim, Germany ("Mercatura") entered into an
agreement under which Mercatura obtained from Sangui the exclusive right to
manufacture, market and distribute the Sangui Nano-Emulsion formulation known as
"Pure Moisture" for five years, starting September 1, 2004, in all German
speaking localities. Under the terms of this agreement Mercatura will pay
Sangui, on a quarterly basis, a per unit license fee for each product package
sold. Mercatura intends to acquire world wide distribution rights at a later
date provided some type of co-op can be formed between Mercatura and Wolfgang
Joop Gmbh. Additionally, Mercatura is granted a right of first refusal on any
new products arrising from the Pure Moisture technology. A Summary of the Terms
of Said Agreement are attached as Exhibit 99.1 to this report.
The information in this Current Report on Form 8-K, including the exhibit,
is furnished under "Item 2. Management's Discussion and Analysis of Financial
Condition" in accordance with SEC Release No. 33-8216. Furthermore, the
information in this Current Report on Form 8-K, including the exhibit, shall not
be deemed to be incorporated by reference into the filings of the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934,
as amended.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the Undersigned, thereunto duly authorized.
Sangui Biotech International, Inc.
(Registrant)
/s/ Wolfgang Barnikol
Date: ______________ ________________
By: Wolfgang Barnikol
Its: President, CEO and CFO
INDEX TO EXHIBITS
Exhibit Number Exhibit
99.1 Summary of Terms of Agreement
* This exhibit is furnished to, but not filed with, the Commission by inclusion
herein.